US FDA seeks input on orphan product regulation
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration will hold a public hearing on 29-30 June to gather stakeholder input on the agency’s review and regulation of devices, biologics and drugs for the treatment, diagnosis or management of rare diseases1.